Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03620084
Other study ID # 2018/2517
Secondary ID SHF/FG713S/2017
Status Recruiting
Phase N/A
First received
Last updated
Start date May 31, 2019
Est. completion date March 2021

Study information

Verified date March 2020
Source Singapore General Hospital
Contact Yan Shan Lee, BSc
Phone (65)63265481
Email lee.yan.shan@sgh.com.sg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Radiation therapy for head and neck cancer (HNC) is associated with the development of swallowing difficulties, or dysphagia. Dysphagia has profound negative effects on the health, nutritional status, and quality of life of HNC survivors. It also puts them at risk of developing life-threatening aspiration pneumonia. Radiation-associated dysphagia can be intractable and not responsive to conventional dysphagia therapy. HNC survivors with chronic severe dysphagia may be dependent on long-term tube feeding.

Expiratory Muscle Strength Training (EMST) is a low-cost, device-driven therapy. It has been studied as an approach to simultaneously improve cough and swallowing functions. During EMST, patients forcefully expire into a one-way spring-loaded valve to strengthen expiratory and submental musculature. The EMST-150 device is available for clinical use in Singapore. In other research studies, it has been shown to improve cough and swallowing in several populations of people with chronic dysphagia, most recently in people with chronic radiation-associated dysphagia.

The investigators propose to study the effect of EMST using the EMST-150 device on cough, airway protection, and swallowing functions of HNC survivors with radiation-associated dysphagia.

The investigators will recruit 40 participants to undergo an 8-week EMST programme, with weekly follow-up to calibrate their EMST device. It is hypothesised that EMST will improve participants' respiratory and swallowing functions. Respiratory function improvement will be shown by increased maximum expiratory pressure and improved cough airflow measures. Swallowing function improvement will be evidenced by reduced aspiration or improved ability to clear aspirated material during videofluoroscopic swallow studies. The investigators also hypothesize carryover effects on other aspects of swallowing, such as improved hyoid and laryngeal excursions, and improved laryngeal vestibule closure.

With the results of this study, the investigators aim to develop better evidence-based rehabilitation programmes for HNC survivors, and those living with chronic dysphagia.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date March 2021
Est. primary completion date March 2021
Accepts healthy volunteers No
Gender All
Age group 21 Years to 95 Years
Eligibility Inclusion criteria

- Chronic dysphagia involving the pharyngeal phase of swallowing for at least 6 months

- Undergone radiation therapy for head and neck cancer

- Penetration and/or aspiration seen on previous clinical videofluoroscopy swallow study (Penetration-Aspiration Scale score of 2 to 8)

- Failure to respond to traditional dysphagia therapy, as indicated by no improvement or only an improvement of 1 point on the Functional Oral Intake Scale, over a period of at least 4 sessions of conventional dysphagia therapy.

Exclusion criteria

- Current pneumothorax

- Severe trismus impeding insertion of rubber mouthpiece into the mouth (as part of treatment protocol)

Patients who have "perforated tympanic membrane", "history of spontaneous pneumothorax" and "history of collapsed lung", will be considered on a case-by-case basis, depending on the stability of their condition. Permission from their primary team doctors, or ENT for tympanic membrane issues, will be sought prior to enrolment into the study. These participants will only be deemed suitable for the study if their primary team doctors, ENT or respiratory doctors agree that they are stable or fully recovered, and that doing EMST will not worsen these conditions. For these patient groups, permission from the patients' primary team doctors, ENT or Respiratory Doctors will be obtained via email. Participants will not be enrolled if there is no written consent indicating approval for subject to be enrolled.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Expiratory Muscle Strength Training (EMST)
The target home practice frequency on the EMST-150 is: 5 repetitions of forceful expiration each time, 5 times daily, 5 days a week for 8 weeks, following the training protocol used by Hutcheson et al. (2017).

Locations

Country Name City State
Singapore Singapore General Hospital Singapore

Sponsors (1)

Lead Sponsor Collaborator
Singapore General Hospital

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum expiratory pressure cm H2O up to 8-week intervention
Primary Change in Penetration Aspiration Scale score An 8-point rating scale of the severity of penetration and aspiration events At baseline and end of 8-week intervention
Secondary Functional Oral Intake Scale A 7-point scale looking at the normalcy of diet consistencies taken by the patient. The lowest score is 1 (No oral intake) and the maximum score is 7 (total oral intake with no restrictions). At baseline and end of 8-week intervention
Secondary Performance Status Scale-Head and Neck An oral intake scale looking at the normalcy of diet consistencies taken by the patient. The scale ranges from 0 (tube-feeding) to 100 (full diet with no restrictions), in increments of 10. At baseline and end of 8-week intervention
Secondary MD Anderson Dysphagia Inventory Self-reported swallowing-related quality of life At baseline and end of 8-week intervention
Secondary Modified Barium Swallow Impairment Profile Seventeen components of swallowing are visually rated on video recordings of the modified barium swallow procedure. At baseline and end of 8-week intervention
See also
  Status Clinical Trial Phase
Recruiting NCT04444869 - Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer Phase 2
Terminated NCT01370876 - Efficacy and Safety Study of Oxaliplatin/5-FU in Patients With Recurrent or Metastatic Head and Neck Cancer Phase 2
Terminated NCT03297957 - Fluorescence Imaging in Head and Neck Cancer N/A
Completed NCT00716157 - Incidence and Patterns of Nausea/Vomiting With Combined Chemotherapy and Radiation N/A
Recruiting NCT04880148 - The Effectiveness of a Thyme and Honey Spray for Oral Toxicities N/A
Completed NCT01017224 - DAHANCA 24: Prognostic Value of 18F-FAZA in Head and Neck Squamous Cell Carcinoma (HNSCC) N/A
Completed NCT00496652 - DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Phase 3
Completed NCT00798655 - Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer Phase 2
Completed NCT00147472 - Positronic Emission Tomography (PET) Imaging in Post Radiation Evaluation of Head and Neck Tumours (PET PREVENT Trial) Phase 3
Completed NCT02880072 - Absorption of Orally Ingested Phosphate in Refeeding Syndrome Phase 4
Completed NCT01917942 - Radiotherapy With Humidification in Head And Neck Cancer Phase 3
Recruiting NCT04865731 - Dermaprazole Cream for Radiation Dermatitis in Head and Neck Cancer Phase 2
Completed NCT02442336 - A Web-Based Multimedia Intervention for Head and Neck Cancer Patients N/A
Completed NCT03102229 - Real-time Activity Monitoring to Prevent Admissions During RadioTherapy N/A
Completed NCT00474825 - Dose Escalation Study of Hyperbaric Oxygen With Radiation and Chemotherapy to Treat Squamous Cell Carcinoma of the Head and Neck Phase 1
Recruiting NCT00180921 - Study of Imatinib (Glivec) in Patients With Adenoid Cystic Carcinoma of the Head and Neck Phase 2
Completed NCT01283334 - A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer Phase 1/Phase 2
Recruiting NCT02557048 - Head and Neck Cancer in Children: A Retrospective Study
Completed NCT02073032 - Incidence and Risk Factors of Refeeding Syndrome N/A
Active, not recruiting NCT02270814 - Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma Phase 2